QR052107B Tablets in Patients With Subacute Cough of Phase Ⅱ Study

PHASE2CompletedINTERVENTIONAL

Enrollment

270

Participants

Timeline

Start Date

June 21, 2023

Primary Completion Date

November 22, 2023

Study Completion Date

December 25, 2023

Conditions

Cough

Interventions

DRUG

QR052107B 100 mg

QR052107B 100 mg QD

DRUG

QR052107B 400 mg

QR052107B 400 mg QD

DRUG

Placebo

placebo QD

Trial Locations (1)

China-Japan Friendship Hospital, Beijing

All Listed Sponsors

lead

Wuhan Createrna Science and Technology Co., Ltd

INDUSTRY